Pitt Shield

Characterization of focused ultrasound-mediated brainstem delivery of intranasally administered agents.

Authors: Ye D, Luan J, Pang H, Yang Y, Nazeri A, Rubin JB, Chen H

Focused ultrasound-mediated intranasal (FUSIN) delivery is a recently proposed technique that bypasses the blood-brain barrier to achieve noninvasive and localized brain drug delivery. The goal of this study was to characterize FUSIN drug delivery outcome in mice with regard to its dependency on several critical experimental factors, including the time interval between IN administration and FUS sonication (T<sub>lag1</sub>), the FUS pressure, and the time for sacrificing the mice post-FUS (T<sub>lag2</sub>). Wild-type mice were treated by FUSIN delivery of near-infrared fluorescent dye-labeled bovine serum albumin (800CW-BSA, used as a model agent). 800CW-BSA was intranasally administered to the mice in vivo, followed by intravenous injection of microbubbles and FUS sonication at the brainstem. Fluorescence imaging of ex vivo mouse brain slices was used to quantify the delivery outcomes of 800CW-BSA. Major organs, along with the nasal tissue and trigeminal nerve, were harvested to assess the biodistribution of 800CW-BSA. The delivery outcome of 800CW-BSA was the highest at the brainstem when T<sub>lag1</sub> was 0.5 h, which was on average 24.5-fold, 5.4-fold, and 21.6-fold higher than those of the IN only, T<sub>lag1</sub> = 1.5 h, and T<sub>lag1</sub> = 4.0 h, respectively. The FUSIN delivery outcome at the lowest pressure level, 0.43 MPa, was on average 1.8-fold and 3.7-fold higher than those at 0.56 MPa and 0.70 MPa, respectively. The mean concentration of 800CW-BSA in the brainstem after FUSIN delivery decreased from 0.5 h to 4.0 h post-FUS. The accumulation of 800CW-BSA was low in the heart, lung, spleen, kidneys, and liver, but high in the stomach and intestines. This study revealed the unique characteristics of FUSIN as a noninvasive, efficient, and localized brain drug delivery technique.

Introduction

Purpose drug delivery without BBB opening
Study Objective Characterize dependency of FUS-mediated intranasal delivery on time interval between IN and FUS, FUS pressure, and post-FUS sacrifice time
Animal model / Human subject Cr.NIH (Swiss) mouse, female, 6-8 weeks, ~25 g
Disease model healthy
MRI or image guidance method Yes ultrasound imaging (L8-17 probe, 8-17 MHz)
Targeted brain region(s) Brainstem ( Side)
Cargo name and characteristics 800CW-labeled bovine serum albumin (BSA), ~1.3 mg/mL
Route of administration intranasal

Outcomes and Safety

Summary of Outcomes FUSIN delivery was highest at Tlag1=0.5h (24.5-fold vs IN only). Lower pressure (0.43 MPa) gave 1.8-fold and 3.7-fold higher delivery than 0.56 and 0.70 MPa. Delivered BSA decreased from 0.5h to 4.0h post-FUS. Minimal systemic exposure except stomach/intestines. No histological damage at 0.70 MPa.

Brain Region

Ultrasound Parameters

Ultrasound instrument VIFU 2000 (Alpinion US Inc.), FUS transducer: center frequency 1.5 MHz, focal depth 60 mm, aperture 60 mm, central opening 38 mm
FUS Frequency 1.5MHz
FUS Pressure 0.43, 0.56, 0.70 MPa (peak negative pressure, corrected for mouse skull attenuation)
FUS Mode pulsed
Pulse duration 6.7ms
Duration of a single FUS session 1min total
Focal Characteristics axial FWHM: 6.04 mm, lateral FWHM: 0.62 mm, focal depth: 60 mm
Treatment frequency single session

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search